68Ga-DOTAGA-IAC PET/CT for Imaging Metastatic and Recurrent Adrenocortical Carcinoma: A Case Series. (February 2023)

• Record Type: Journal Article
• Authors: Pandey, Somit; Walia, Rama; Kumar, Rajender; Chopra, Sejal; Rana, Nivedita; Chatterjee, Debajyoti; Satz, Stanley; Mittal, Bhagwant Rai; Shukla, Jaya
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 2(2023)
• Page Start: e95
• Page End: e98
• Publication Date: 2023-02
• Subjects: ACC -- CT -- MRI -- PET/CT -- DOTAGA-IAC -- αvβ3 integrin; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004497
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: Adrenocortical carcinoma (ACC) is a rare malignancy with a prevalence of 1 to 2 cases/million/year. The diagnosis depends upon endocrine workup followed by imaging with CT, MRI, and 18 F-FDG PET/CT. The treatment includes surgical resection, debulking surgery, chemotherapy, and radiotherapy. However, patients do not respond well to any of the available therapies. We present noninvasive imaging of histopathology-proven ACC patients using 68 Ga-DOTAGA-IAC PET/CT, specific for integrin αv β3 . 68 Ga-DOTAGA-IAC PET/CT 45 minutes after IV injection showed a decent tumor-to-background ratio and could be used as a promising radiotracer for metastatic and recurrent ACC.